Mazdutide is a dual receptor agonist that binds both GLP-1 and glucagon receptors. The combined activation engages an integrated metabolic response — reduced appetite and slowed gastric emptying from the GLP-1 arm, alongside increased energy expenditure and thermogenesis from the glucagon arm.
Approved in China in June 2025 for obesity and type 2 diabetes, Mazdutide is administered as a once-weekly subcutaneous injection. Phase trials reported up to ~15% body-weight reduction over 24 weeks.
- Dual GLP-1 / glucagon receptor research
- Appetite, satiety and gastric-emptying studies
- Thermogenesis and energy-expenditure investigation
- Glycemic-control and insulin-secretion research
- Purity
- 99% (HPLC)
Store between 2 °C and 8 °C, protected from light. Do not freeze.
For research and laboratory use only. Not for human or veterinary consumption.
How to run this compound.
Add bacteriostatic water to the sealed vial. Swirl — do not shake. Refrigerate after reconstitution.
Reconstitute with bacteriostatic water. Subcutaneous administration on protocol cadence.
Run on the protocol schedule. The system rewards consistency over intensity.
Pair with complementary REFRAME lines. See suggestions below.
